ClinicalTrials.gg
CompletedNCT00776841Updated Nov 3, 2010

A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers

A Phase 1 interventional study of Aramchol and Aramchol in Healthy, sponsored by Galmed Medical Reserch. Completed at 1 site in Israel. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-11-03.

Sponsored by Galmed Medical Reserch · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Hypercholesterolemia with a site in Israel — 4 open to participants now, 10 under way, 9 of them phase 3. Hypercholesterolemia · Israel.

Enrollment
36th of 42
41 · median 573
Started
2008
with 2 others
Phase 1
Only one
of the 43
Registered
14th of 43
by date

Among the 43 studies in Hypercholesterolemia with a site in Israel, this one is the 36th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2008, is the only one in phase 1, and was the 14th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

4 of the 43 studies in Hypercholesterolemia with a site in Israel are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 50 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Hypercholesterolemia with a site in Israel, or all of them as a file.
02

Study summary

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers.

Primary Objectives:

  1. To assess and characterize the safety and tolerability of Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
  2. To assess the pharmacokinetics of Aramchol at the administered doses
Read the detailed description

Number of Subjects:

Total: A total of 46 healthy subjects will be enrolled. Part A: Sixteen (16) subjects will participate in four, 8-person dosing periods. Each cohort will be alternately dosed twice.

Part B: Thirty (30) subjects will be enrolled in two, 15-person dose-ascending cohorts.

Main Inclusion Criteria:

Part A: Healthy male volunteers aged 18-50 (inclusive) years who have provided written informed consent Part B: Mildly overweight (25\<BMI\<33), with fasting cholesterol levels of 200-300 mg/% or LDL 100-180 mg/% and triglycerides \< 200 mg/%, otherwise healthy male volunteers aged 18-50 (inclusive) years, who have provided written informed consent

03

Conditions studied

  • Healthy

Keywords

  • Phase-I
  • Hypercholesterolemia
  • Obesity
  • fatty liver
  • Part A: Healthy male volunteers Part B: Mildly overweight, otherwise healthy hypercholesterolemic male volunteers
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Part A: Healthy male volunteers aged 18-50 (inclusive) years who have provided written
  • Part B: Mildly overweight (25\< \<33), with fasting cholesterol levels of 200-300 mg/% or LDL 100-180 mg/% and triglycerides \< 200 mg/%, otherwise healthy male volunteers aged 18-50 (inclusive) years, who have provided written informed consent

Major Exclusion Criteria:

  • History of significant neurological (including history of seizures or EEG abnormalities), renal, cardiovascular (including known structural cardiac abnormalities or hypertension), respiratory (asthma), endocrinological, gastrointestinal, hematopoietic disease, neoplasm, psychological (marked anxiety, tension or agitation) or any other medical disorder, which in the investigator's judgment contraindicate administration of the study medications.
  • History of drug or alcohol abuse.
  • Known allergy to any drug. Known allergy to any drug.
  • Clinically significant abnormalities found in the screening physical exam.
  • Significant abnormalities in clinical laboratory parameters (hematology, biochemistry, urinalysis) determined within 40 days of the start of the study and on Day (-1) before first dosing session. Parameters to be measured are those shown in Appendix 2.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo control single dose

    Drug: Aramchol

  • Experimental
    Dose 1

    Dose 30 mg

    Drug: Aramchol

  • Experimental
    Dose 2

    Dose 100 mg

    Drug: Aramchol

  • Experimental
    Dose 3

    Dose 300 mg

    Drug: Aramchol

  • Experimental
    Dose 4

    Dose 900 mg

    Drug: Aramchol

  • Experimental
    Dose 1 repeated

    Dose 30 mg for 4 days

    Drug: Aramchol

  • Experimental
    Dose 2 repeated

    Dose high for 4 days

    Drug: Aramchol

Interventions

  • 1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)

    Also known as: 3β-arachidylamido-7α,12α,dihydroxy 5β-cholan-24-oic acid), fatty-acid bile-acid conjugate

  • Oral Aramchol at dose 30 mg to 900 mg

  • Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days

06

What researchers measure

Primary outcomes

  1. To assess safety and tolerability and Pharmacokinetics of Aramchol at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, subjects receiving multiple doses (Part B)

    Time frame: day 1 to 6

Secondary outcomes

  1. To assess and characterize the drug effect on lipid profile and functional pharmacodynamics following single and multiple dose administrations.

    Time frame: day 1 to 6

07

Study locations

1 site
  • Tasmc Clinical Research Center
    Tel-Aviv, 64239, Israel
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Sep 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2008
First posted
Oct 21, 2008
Start
Sep 2008
Primary completionActual
Sep 2009
CompletionActual
Oct 2009
Last update
Nov 3, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00776841
Lead sponsor
Galmed Medical Reserch
First posted
Oct 21, 2008
Start date
Sep 2008
Primary completion
Sep 2009
Completion
Oct 2009
Last update
Nov 3, 2010

Study contacts

Jacob Atsmon, M.D.
principal investigator · TASMC CLINICAL RESEARCH CENTER

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aramchol

Start the discussion